Table 2.

First-line treatment and clinical response stratified according to treatment modalities

Modality	Number of patients	CR, n (%)	PR, n (%)	SD, n (%)	PD, n (%)	Death, n (%)	Relapse, n (%)	Final outcomes
Watch and wait	2	0	0	2 (100)a	0	0	0	CR (1)/SD (1)
Surgery
VATS lobectomy	4	4 (100)	0	0	0	0	0	CR (4)
VATS wedge resection	2	2 (100)	0	0	0	0	0	CR (2)
Systemic chemotherapy
CHOP	6	5 (83.3)	1 (16.7)b	0	0	1 (16.7)	2 (33.3)	CR (5)/death (1)
CVP	4	3 (75.0)	1 (25.0)c	0	0	0	2 (50.0)	CR (4)
R-CHOP	1	1 (100)	0	0	0	0	0	CR (1)
R-CVP	22	15 (68.2)	5 (22.7)d	0	2 (9.1)	1 (4.6)	7 (31.8)	CR (19)/SD (2)/death (1)
BR	1	1 (100)	0	0		0	0	CR (1)
Treatment response	42	31 (73.8)	7 (16.7)	2 (4.8)	2 (4.8)	2 (4.8)	11 (28.6)	CR (37)/SD (3)/death (2)

BR, bendamustine and rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete remission; CVP, cyclophosphamide, vincristine, and prednisone; MALT, mucosa-associated lymphoid tissue, PR, partial remission; PD, progressive disease; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; SD, stable disease; VATS, video-assisted thoracic surgery.

^aTwo patients were diagnosed with pulmonary MALT lymphoma via transbronchial lung biopsy and, despite having remnant lesions, opted for a watch-and-wait approach. One patient exhibited SD with a follow-up duration of 24.1 months, while the other achieved complete remission after undergoing eight cycles of R-CVP due to disease progression.

^bThis patient relapsed 35.4 months after attaining CR and received supportive care due to age and low-performance status, ultimately succumbing to disease progression.

^cThis patient finally achieved CR after six cycles of CVP and has maintained CR since.

^dOne of the patients who achieved PR after four cycles of R-CVP died during the fifth cycle of R-CVP due to an underlying chronic hepatitis B flare-up.